Breaking News Instant updates and real-time market news.

SANM

Sanmina

$27.70

0.1 (0.36%)

, CDNS

Cadence Design

$36.75

-0.27 (-0.73%)

19:00
04/23/18
04/23
19:00
04/23/18
19:00

On The Fly: After Hours Movers

UP AFTER EARNINGS: Sanmina (SANM) up 13.7%... Cadence Design (CDNS) up 9.7%... Helix Energin (HLX) up 9.4%... Trimble (TRMB) up 4.9%... Rush Enterprises (RUSHA) up 3.0%... SLM Corp (SLM) up 1.9%... Zions Bancorporation (ZION) up 1.8%... Ameriprise Financial (AMP) up 1.2%... Alphabet (GOOG) up 0.1%. ALSO HIGHER: Zymeworks (ZYME) up 2.6% after Celgene collaboration... Tandem Diabetes (TNDM) up 3.5% after increased insulin pump distribution... La Quinta (LQ) up 2.3% after being named winner of Ira Sohn investor conference... BP (BP) up 0.5% after Goldman Sachs upgrade. DOWN AFTER EARNINGS: Donegal (DGICA) down 6.0%... TD Ameritrade (AMTD) down 2.8%... Whirlpool (WHR) down 2.2%... Tivity Health (TVTY) down 1.3%... Brown & Brown (BRO) down 0.7%... Barrick Gold (ABX) down 0.5%... Owens-Illinois (OI) down 0.4%. ALSO LOWER: Epizyme (EPZM) down 19.9% after FDA placed a hold on tazemetostat clinical trials... Assured Guaranty (AGO) down 4.8% after negative view from Greenlight's Einhorn at Ira Sohn... Casa Systems (CASA) down 4.4% after stock sale for holders... Bed Bath & Beyond (BBBY) down 0.6% after Wells Fargo initiated at Underperform.

SANM

Sanmina

$27.70

0.1 (0.36%)

CDNS

Cadence Design

$36.75

-0.27 (-0.73%)

HLX

Helix Energy

$6.24

-0.245 (-3.78%)

TRMB

Trimble

$36.13

-0.44 (-1.20%)

RUSHA

Rush Enterprises

$43.00

-0.3 (-0.69%)

SLM

Sallie Mae

$11.68

0.015 (0.13%)

ZION

Zions Bancorp

$54.27

0.47 (0.87%)

AMP

Ameriprise

$145.45

1.74 (1.21%)

GOOG

Alphabet

$1,067.70

-5.03 (-0.47%)

ZYME

Zymeworks

$12.08

0.095 (0.79%)

TNDM

TNDM

LQ

La Quinta

$19.55

0.09 (0.46%)

BP

BP

$43.92

0.415 (0.95%)

DGICA

Donegal Group

$15.07

-0.11 (-0.72%)

AMTD

TD Ameritrade

$61.21

-0.04 (-0.07%)

WHR

Whirlpool

$150.31

0.885 (0.59%)

TVTY

Tivity Health

$39.50

-0.6 (-1.50%)

BRO

Brown & Brown

$26.56

0.6 (2.31%)

ABX

Barrick Gold

$12.93

-0.23 (-1.75%)

OI

Owens-Illinois

$21.76

0.13 (0.60%)

EPZM

Epizyme

$15.25

-0.65 (-4.09%)

AGO

Assured Guaranty

$35.90

-0.81 (-2.21%)

CASA

Casa Systems

$29.81

-0.35 (-1.16%)

BBBY

Bed Bath & Beyond

$17.35

0.22 (1.28%)

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 08

    May

  • 09

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 12

    Jun

SANM Sanmina
$27.70

0.1 (0.36%)

01/23/18
NEED
01/23/18
NO CHANGE
Target $33
NEED
Buy
Sanmina price target lowered to $33 from $45 at Needham
Needham analyst Sean Hannan lowered his price target on Sanmina to $33, saying the company's "ugly" Q1 preliminary result is the continuation of prior challenges. Hannan also cites a "slowness in new ramps, some cancellations, and tighter materials supply". The analyst notes that he still expects the aggregate ramp schedule to remain strong in the second half of 2018 and calls most issues "transitory", keeping his Buy rating on Sanmina.
04/13/18
SBSH
04/13/18
UPGRADE
SBSH
Buy
Citi upgrades Sanmina to Buy on conservative sales estimates
Citi analyst Jim Suva upgraded Sanmina to Buy from Neutral with a price target of $32. The analyst believes consensus sales estimates are too conservative and that fundamental softness in recent quarters is already priced in. Suva also upgraded the Electronics Manufacturing Services sector citing strong demand.
01/23/18
CHLM
01/23/18
NO CHANGE
Target $37
CHLM
Buy
Sanmina price target lowered to $37 from $44 at Craig-Hallum
Craig-Hallum analyst Christian Schwab lowered his price target for Sanmina to $37 from $44 following "disappointing" results and guidance. The analyst reiterates a Buy rating on the shares.
04/13/18
SBSH
04/13/18
UPGRADE
SBSH
Buy
Sanmina upgraded to Buy from Neutral at Citi
CDNS Cadence Design
$36.75

-0.27 (-0.73%)

04/05/18
DADA
04/05/18
UPGRADE
Target $45
DADA
Buy
Cadence Design upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Thomas Diffely upgraded Cadence Design (CDNS) to Buy from Neutral and kept his $45 price target. Diffely points to the divergence of strong business activity against weak stock performance for the company, saying the 20% slide since the end of January creates an "attractive buying opportunity". The analyst notes that Cadence Design is gaining market share, mainly from Mentor Graphics (MENT) and no longer trades at a "meaningful" premium to Synopsys (SNPS), adding that he is positive on the company's short and long-term electronic design automation opportunity.
02/01/18
FBCO
02/01/18
NO CHANGE
Target $43
FBCO
Neutral
Cadence Design price target raised to $43 from $37 at Credit Suisse
Credit Suisse analyst Farhan Ahmad raised his price target for Cadence Design to $43 from $37, while reiterating a Neutral rating on the shares as he views the results as broadly in-line with his preview expectations.
10/30/17
DADA
10/30/17
NO CHANGE
Target $43
DADA
Neutral
Cadence Design price target raised to $43 from $36 at DA Davidson
DA Davidson analyst Thomas Diffely raised his price target on Cadence Design to $43 after Q3 results, saying design activity remains robust, memory market is emerging as a new driver, and the new product pipeline has never been better. Diffely says the company's introduction of new products positions it for the "emerging era of memory-centric Big Data" but also keeps his Neutral rating on Cadence Design given the 27-times PE valuation.
10/11/17
RBCM
10/11/17
NO CHANGE
Target $45
RBCM
Outperform
Cadence Design price target raised to $45 from $39 at RBC Capital
RBC Capital analyst Mitch Steves raised his price target on Cadence Design to $45 ahead of the company's earnings, citing potential upside from its Palladium Z1 platform and attractive valuation relative to other small cap software companies. Steves says he remains positive on Cadence Design fundamentals, but also adds that an M&A premium in the stock is unwarranted at this time.
HLX Helix Energy
$6.24

-0.245 (-3.78%)

10/12/17
MSCO
10/12/17
NO CHANGE
Target $11
MSCO
Overweight
Helix Energy worth at least $11 per share, says Morgan Stanley
Helix Energy shares have risen almost 20% since The Wall Street Journal reported that the company is exploring strategic alternatives, but Morgan Stanley analyst Ole Slorer believes the shares still have "meaningful upside," estimating that its assets and backlog make it worth at least $11 per share. Slorer has raised the firm's price target on the stock to $11 from $8 given the analysis and keeps an Overweight rating on the stock.
01/16/18
BOFA
01/16/18
DOWNGRADE
BOFA
Underperform
Helix Energy downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Timna Tanners downgraded Helix Energy to Underperform and based on valuation cut its price target to $7.50 from $8.
09/05/17
BOFA
09/05/17
INITIATION
Target $7
BOFA
Neutral
Helix Energy initiated with a Neutral at BofA/Merrill
BofA/Merrill analyst J.B. Lowe initiated Helix with a Neutral and a $7 price target due to weak offshore activity for the foreseeable future.
09/27/17
PIPR
09/27/17
DOWNGRADE
Target $7.3
PIPR
Neutral
Helix Energy downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Ian Macpherson downgraded Helix Energy Solutions Group to Neutral citing valuation with the shares up 50% since early June. The analyst views the current valuation as "fair" and upped his price target on the name to $7.30 from $7.
TRMB Trimble
$36.13

-0.44 (-1.20%)

01/31/18
OPCO
01/31/18
NO CHANGE
Target $50
OPCO
Outperform
Trimble price target raised to $50 from $45 at Oppenheimer
Oppenheimer analyst Colin Rusch raised his price target for Trimble to $50 from $45 ahead of Q4 earnings report as he expects the company to deliver high-single-digit year over year organic revenue growth boosted by recent acquisitions. The analyst reiterates an Outperform rating on the shares.
04/17/18
BREN
04/17/18
UPGRADE
Target $44
BREN
Buy
Trimble upgraded to Buy from Hold at Berenberg
Berenberg analyst Gal Munda upgraded Trimble Navigation to Hold with an unchanged price target of $44. Following the stock's recent underperformance, the valuation gap between Trimble and its peers is too large, especially when considering the company's "strong" growth outlook, Munda tells investors in a research note.
01/25/18
PIPR
01/25/18
NO CHANGE
Target $49
PIPR
Overweight
Piper sees potential upside to Trimble's Q4 after Caterpillar sales
Piper Jaffray analyst Brett Wong says he continues to see strength in Trimble Navigation's (TRMB) key end markets. The company's joint venture partner Caterpillar (CAT) reported yesterday ongoing acceleration in construction equipment sales through the back-end of 2017, Wong tells investors in a research note. He believes this drives potential upside for Trimble's Q4. The analyst keeps a Buy rating on the shares with a $49 price target.
02/09/18
BREN
02/09/18
NO CHANGE
Target $44
BREN
Hold
Trimble post-earnings reaction doesn't match underlying strength, says Berenberg
Berenberg analyst Gal Munda raised his price target on Trimble to $44 from $41 following the company's "strong" Q4 performance and to reflect the re-rating of some of its peers. Q1 EPS guidance was the "only negative" coming out of its report, though Q1 "does not tell the whole story" and the company's management is typically conservative, according to Munda, who keeps a Hold rating on Trimble shares but believes the post-earnings reaction could present a short-term buying opportunity.
RUSHA Rush Enterprises
$43.00

-0.3 (-0.69%)

02/27/18
BUCK
02/27/18
UPGRADE
Target $53
BUCK
Buy
Rush Enterprises upgraded to Buy at Buckingham on attractive risk/reward
As reported earlier, Buckingham analyst Neil Frohnapple upgraded Rush Enterprises to Buy From Neutral with a $53 price target. The analyst believes that the risk/reward profile is "attractive" after some recent weakness in the stock price given the company's growth profile for the next few years. Frohnapple also notes Rush Enterprises "highly profitable aftermarket business" and the "all makes parts initiative" as positive catalysts in his upgrade.
02/27/18
BUCK
02/27/18
UPGRADE
BUCK
Buy
Rush Enterprises upgraded to Buy from Neutral at Buckingham
02/20/18
BMOC
02/20/18
NO CHANGE
Target $45
BMOC
Market Perform
Rush Enterprises price target lowered to $45 from $50 at BMO Capital
BMO Capital analyst Joel Tiss lowered his price target on Rush Enterprises to $45 to reflect the decline in the stock price as a result of concerns over peaking North America heavy duty truck cycle. The analyst also points to the management's earnings call suggestion that the company's market share could decline this year "as more over-the-road fleets return to the market". Tiss keeps his Market Perform rating on Rush Enterprises, stating that the company needs to show that it can grow earnings in spite of declining new and used commercial vehicle sales.
02/09/18
SPHN
02/09/18
UPGRADE
Target $65
SPHN
Overweight
Rush Enterprises upgraded to Overweight from Equal Weight at Stephens
Stephens analyst Brad Delco upgraded Rush Enterprises to Overweight from Equal Weight ahead of the company's Q4 report, noting that his estimates remain above the consensus view. Delco thinks the long-term initiatives in place at Rush could ultimately drive +$6.00 of EPS power by 2022, he tells investors. He raised his price target on Rush shares to $65 from $57.
SLM Sallie Mae
$11.68

0.015 (0.13%)

01/08/18
OPCO
01/08/18
INITIATION
Target $17
OPCO
Outperform
Sallie Mae initiated with an Outperform at Oppenheimer
As reported earlier, Oppenheimer analyst Ben Chittenden initiated Sallie Mae with an Outperform rating and a price target of $17, citing a "secular mix shift away from Federal funding of educational tuition and toward private lenders" where the company has a leading market share. The analyst says Sallie Mae will continue to benefit from better efficiency ratio, estimating mid-30s % versus "40% range" currently.
01/08/18
OPCO
01/08/18
INITIATION
OPCO
Perform
Navient initiated with a Perform at Oppenheimer
As reported earlier, Oppenheimer analyst Ben Chittenden initiated Navient (NAVI) with a Perform rating. Chittenden says the bulk of the company revenue still comes from its legacy loan book and private student loan portfolio, and both of those segments are under pressure. The analyst adds that 2019 could mark a key turning point, when Navient's non-compete agreement with Sallie Mae (SLM) expires, allowing it to originate private student loans again.
01/08/18
OPCO
01/08/18
INITIATION
Target $17
OPCO
Outperform
Sallie Mae initiated with an Outperform at Oppenheimer
Oppenheimer analyst Ben Chittenden started Sallie Mae with an Outperform rating and $17 price target.
04/04/18
WELS
04/04/18
INITIATION
Target $13.5
WELS
Outperform
Sallie Mae initiated with an Outperform at Wells Fargo
Wells Fargo analyst Michael Kaye started Sallie Mae with an Outperform rating and $13.50 price target. The analyst views the valuation as attractive with the shares trading at 9.5 times his 2019 earnings estimate. This is a "significant" discount to the 20%-plus estimated earnings growth rate from 2017 to 2020, Kaye tells investors in a research note.
ZION Zions Bancorp
$54.27

0.47 (0.87%)

03/22/18
UBSW
03/22/18
INITIATION
Target $67
UBSW
Buy
Zions Bancorp initiated with a Buy at UBS
UBS analyst Brock Vandervliet started Zions Bancorp with a Buy rating and $67 price target. The analyst rolled out coverage last night on the Mid-Cap Banks. He sees performance differentiation "playing out more starkly" than investors may expect with "increasingly advantaged and disadvantaged participants."
03/21/18
UBSW
03/21/18
INITIATION
UBSW
Buy
Zions Bancorp initiated with a Buy at UBS
03/15/18
RAJA
03/15/18
UPGRADE
Target $61
RAJA
Outperform
Zions Bancorp upgraded to Outperform on valuation, growth at Raymond James
As previously reported, Raymond James upgraded Zions Bancorp to Outperform from Market Perform and established a $61 price target. Analyst David Long came away from recent management meetings with a better appreciation of risk reduction efforts, profitability improvements, increasing capital return levels, and positive operating leverage. Long believes shares are undervalued given earnings growth and improving profitability metrics.
03/15/18
RAJA
03/15/18
UPGRADE
RAJA
Outperform
Zions Bancorp upgraded to Outperform from Market Perform at Raymond James
AMP Ameriprise
$145.45

1.74 (1.21%)

08/02/17
SBSH
08/02/17
NO CHANGE
Target $166
SBSH
Buy
Ameriprise price target raised to $166 from $146 at Citi
Citi analyst Suneet Kamath raised his price target for Ameriprise Financial to $166 following meetings with management and keeps a Buy rating on the shares. The company feels good about the advisor productivity it is seeing, the analyst tells investors in a research note.
01/19/18
RHCO
01/19/18
NO CHANGE
Target $180
RHCO
Hold
Ameriprise price target raised to $180 from $165 at SunTrust
SunTrust analyst Douglas Mewhirter raised his price target on Ameriprise to $180 and kept his Hold rating after the company's preliminary outlook on the impact of new U.S. tax legislation and losses attributed to California wildfires. Mewhirter lowers his FY17 EPS forecast to $9.64 from $11.84 on the loss provisioning, but raises his FY18 view to $14.33 from $13.42 on the lower tax rate implications.
03/02/18
EVER
03/02/18
DOWNGRADE
EVER
In Line
Ameriprise downgraded to In Line from Outperform at Evercore ISI
03/02/18
DBAB
03/02/18
INITIATION
Target $217
DBAB
Buy
Ameriprise initiated with a Buy at Deutsche Bank
UBS analyst John Nadel started Ameriprise Financial with a Buy rating and $217 price target. The analyst believes the shares are "on sale" at current levels.
GOOG Alphabet
$1,067.70

-5.03 (-0.47%)

04/13/18
NOMU
04/13/18
INITIATION
Target $21
NOMU
Reduce
Nomura Instinet puts Reduce rating on Dropbox with $21 price target
Nomura Instinet analyst Christopher Eberle last night initiated Dropbox (DBX) with a Reduce rating and $21 price target. The shares closed yesterday up 95c to $33.27. Dropbox's "consistently low" penetration rates, "extremely low" conversion rates, and lack of enterprise salesforce creates little room for upside potential, Eberle tells investors in a research note. If trends do not improve, the shares have "significant downside," the analyst argues. Eberle admits, however, that Dropbox has positioned itself as a top player in the backup storage and workplace collaboration space. The company is a "staunch competitor" to Microsoft's (MSFT) OneDrive, Google's (GOOG, GOOGL) Drive and Apple's (AAPL) iCloud, Eberle contends.
04/19/18
DBAB
04/19/18
NO CHANGE
Target $1350
DBAB
Buy
Deutsche bullish on Alphabet shares into Q1 results
Deutsche Bank analyst Lloyd Walmsley says he's bullish on Alphabet shares into the company's Q1 results. The analyst believes Street estimates are achievable and sees "tempered investor sentiment" on the top and bottom lines. He thinks an in-line quarter is enough for Alphabet given the current sentiment. Walmsley recommends adding to positions into the print and keeps a Buy rating on the shares. He trimmed his price target for Alphabet to $1,350 from $1,375.
04/20/18
FBCO
04/20/18
NO CHANGE
Target $1350
FBCO
Outperform
Alphabet target price lowered to $1350 from $1400 at Credit Suisse
Credit Suisse analyst Stephen Ju lowered his price target on Alphabet modestly to $1350 from $1400 ahead of its Q1 results on April 23. In a research note to investors, Ju, who has an Outperform rating on shares, said he has rebuilt his Google model to add incremental segment granularity and moderated his YouTube TV revenue estimates to assume this service will be U.S. only. Ju said Alphabet remains his favorite name in the sector given the longer-term opportunity that the stock continues to present.
04/18/18
NOMU
04/18/18
NO CHANGE
Target $65
NOMU
Buy
Nomura Instinet ups Square price target to $65 on bitcoin boost
Nomura Instinet analyst Dan Dolev raised his price target for Square (SQ) shares to $65 from $64 saying the impact from bitcoin could be meaningful. The stock closed yesterday up $2.10 to $49.13. Opening Square Cash for bitcoin trading earlier this year could drive a "sizable boost" to revenue and profits, driving up to 10% potential upside to adjusted EBITDA guidance, Dolev tells investors in a research note. He sees bitcoin as helping to offset Square's rising investment costs to broaden its international presence. In asking if bitcoin will reshape the future of payments as Square CEO Jack Dorsey often argues, or if it will just be a passing fad, Dolev points out that the company's correlation with the cryptocurrency has been on a downward trend. Square shares are now less correlated with bitcoin than PayPal (PYPL), the payment networks or Alphabet (GOOG, GOOGL), Dolev contends. He maintains a Buy rating on Square.
ZYME Zymeworks
$12.08

0.095 (0.79%)

09/07/17
09/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. trivago (TRVG) downgraded to Neutral from Buy at BofA/Merrill with analyst Nat Schindler citing a surprise lowering of its 2017 revenue growth target to 40% from 50% and reduced adjusted EBITDA to down year-over-year. 2. Carrizo Oil & Gas (CRZO) downgraded to Neutral from Buy at Mizuho with analyst Timothy Rezvan saying Carrizo faces too many near-term headwinds and doesn't see Net Asset Value upside driving near-term stock outperformance. 3. Varian Medical (VAR) downgraded on valuation, macro concerns at BTIG with analyst Sean LAvin saying he downgraded the stock "mainly on valuation." However, he also believes that the company's results could be hurt by "instability in Korea and multiple hurricanes." 4. Zymeworks (ZYME) assumed with an Underweight from Overweight at Barclays with analyst Gena Wang saying she has low expectations for the company's lead asset HER2 dispecific antibody ZW25 in HER and high and medium expressed breast cancer. 5. Sealed Air (SEE) downgraded to Neutral from Buy at Citi with analyst Anthony Pettinari saying the company's annual guidance is at risk due to resin headwinds post Hurricane Harvey. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/17
05/24/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Shake Shack (SHAK) initiated with an Overweight at Piper Jaffray. 2. Zymeworks (ZYME) initiated with a Buy at Citi. 3. Murphy Oil (MUR) initiated with a Buy at KLR Group. 4. Atlas Financial (AFH) initiated with an Outperform at JMP Securities. 5. Emerald Expositions Events (EEX) initiated with a Buy at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/17
LEHM
09/06/17
DOWNGRADE
Target $8
LEHM
Underweight
Zymeworks assumed with an Underweight from Overweight at Barclays
Barclays analyst Gena Wang assumed coverage of Zymeworks and double downgraded the shares to Underweight from the firm's previous rating of Overweight. She cut her price target to $8 from $20. The analyst has low expectations for the company's lead asset HER2 dispecific antibody ZW25 in HER and high and medium expressed breast cancer.
03/19/18
RAJA
03/19/18
INITIATION
Target $18
RAJA
Outperform
Zymeworks initiated with an Outperform at Raymond James
Raymond James analyst David Novak initiated Zymeworks with an Outperform and $18 price target telling investors the company represents "Canada's Mother Of All Biotechnology plays" given its robust platform technologies which have significant partner interest, and a growing pipeline of wholly owned assets. .
TNDM TNDM

04/10/18
PIPR
04/10/18
NO CHANGE
PIPR
Neutral
Too early to call Tandem Diabetes revenue beat a trend, says Piper Jaffray
Piper Jaffray analyst JP McKim noted that Tandem Diabetes announced preliminary Q1 revenue that beat his estimate of $24.8M and the consensus view near $25M. McKim, who thinks the company "clearly benefited" from the exit of Animas from the U.S. market, is incrementally more positive on Tandem but awaits more evidence of an accelerating growth trend before changing his Neutral rating on the stock.
03/28/18
COWN
03/28/18
UPGRADE
Target $7
COWN
Outperform
Tandem Diabetes upgraded to Outperform on market share gains at Cowen
As reported previously, Cowen analyst Doug Schenkel upgraded Tandem Diabetes (TNDM) to Outperform from Market Perform. The analyst cited his recent diabetes devices survey, which suggested the company is picking up market share from Animas' market exit and he sees excitement about its integration with Dexcom (DXCM). Schenkel raised his price target to $7 from $5 on Tandem Diabetes shares.
04/17/18
PIPR
04/17/18
NO CHANGE
PIPR
J&J commentary positive for pure-play spine names, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien is out discussing derivative calls following Johnson & Johnson's (JNJ) Q1 results. The orthopedic market looked relatively stable, though Hips were notably softer than expected, O'Brien tells investors in a research note. He believes Stryker (SYK) is "clearly taking market share," which he views as an incremental negative for Zimmer Biomet (ZBH). On Spine, some U.S. weakness was expected, but J&J's results could be viewed as concerning given continued weakness since Q3 of 2017, the analyst adds. He thinks the end markets "are ok" and the commentary on J&J losing share benefits pure-play spine names NuVasive (NUVA), Globus Medical (GMED), SeaSpine (SPNE) and K2M Group (KTWO). He believes the pure-plays continue to out-innovate and take share despite the weakness in the overall category. Johnson & Johnson's results also show that the U.S. lens market remains strong and is shifting to 1-Days lenses from weeklies/monthlies, which is a positive for Cooper Companies (COO), O'Brien contends. Lastly, the analyst says the decline in J&J's U.S. diabetes franchise from the Animas exit was faster than expected. This is good for the pump names Insulet (PODD) and Tandem Diabetes (TNDM) and a slight negative for Dexcom (DXCM) as some of those will end up at Medtronic (MDT), O'Brien argues. He continues to believe that both Insulet and Tandem "will gain more than their fair share" of Animas patients.
03/28/18
COWN
03/28/18
UPGRADE
Target $7
COWN
Outperform
Tandem Diabetes upgraded to Outperform from Market Perform at Cowen
Cowen analyst Doug Schenkel upgraded Tandem Diabetes to Outperform and raised his price target for the shares to $7 from $5.
LQ La Quinta
$19.55

0.09 (0.46%)

02/13/18
MSCO
02/13/18
NO CHANGE
Target $23
MSCO
Overweight
La Quinta deal to join Wyndham system underappreciated, says Morgan Stanley
Morgan Stanley analyst Thomas Allen makes the case in a new note to investors that the market is missing the benefits La Quinta (LQ) gains from joining Wyndham's (WYN) system. For example, he estimates La Quinta hotels will be able to drop to below a 20% OTA mix and lower their average commission rate to about 15% given this will be the first time they will be part of a larger brand network. Noting that La Quinta shareholders will still own the hotels via the spin out into the Corepoint REIT, Allen raised his price target on the stock to $23 from $21 and keeps an Overweight rating on La Quinta shares.
03/02/18
SPIN
03/02/18
DOWNGRADE
SPIN
Hold
La Quinta downgraded to Hold from Buy at Spin-Off Research
04/02/18
OPCO
04/02/18
INITIATION
Target $135
OPCO
Outperform
Wyndham initiated with an Outperform at Oppenheimer
Oppenheimer analyst Ian Zaffino started Wyndham Worldwide (WYN) with an Outperform rating and $135 price target, calling the company the leader in the economy/upper-economy hotel space and saying he believes the planned acquisition of La Quinta (LQ) will also make it the leader in the premier midscale segment.
01/22/18
WELS
01/22/18
DOWNGRADE
Target $20.5
WELS
Market Perform
La Quinta downgraded to Market Perform after Wyndham deal at Wells Fargo
As previously reported, Wells Fargo analyst Jeffrey Donnelly downgraded La Quinta (LQ) to Market Perform from Outperform following its deal to dispose of its management/franchise operations to Wyndham (WYN). The overall value of the sale of the LaQuinta brand and the CorePoint Lodging REIT spinoff is slightly lower than his prior expectation, said Donnelly. He notes that Wyndham is purchasing the LaQuinta brand operations for $8.40 per share net and now believes the equity in CorePoint is $11.75-$12.50 per share, which implies a value range of $20.15-$20.90 for the combined entity. Shares of La Quinta are currently trading near $20 per share.
BP BP
$43.92

0.415 (0.95%)

04/20/18
STFL
04/20/18
NO CHANGE
Target $42
STFL
Buy
Golar LNG price target raised to $42 from $36 at Stifel
Stifel analyst Benjamin Nolan raised his price target on Golar LNG (GLNG) to $42 from $36 after the company announced a Heads of Terms to provide the first FLNG unit, with an option to provide a second, to BP (BP) and Kosmos (KOS) on their Tortue field in offshore Mauritania and Senegal. The analyst views this announcement as having "enormous upside potential" and as one of a "potentially lengthy list of possible catalysts" for Golar LNG, he tells investors. Nolan maintains a Buy rating on Golar LNG shares.
03/29/18
SBSH
03/29/18
UPGRADE
SBSH
Buy
BP upgraded to Buy from Neutral at Citi
Citi analyst Alastair Syme upgraded BP to Buy citing valuation.
04/23/18
GSCO
04/23/18
UPGRADE
GSCO
Buy
BP upgraded to Buy from Neutral at Goldman Sachs
04/11/18
DBAB
04/11/18
NO CHANGE
DBAB
Deutsche upgrades Eni to Buy, downgrades Total to Hold
Deutsche Bank analyst Lucas Herrmann coupled an upgrade of Eni SpA (E) to Buy from Hold with a downgrade of Total (TOT) to Hold from Buy. The analyst sees improving fundamentals and free cash flow yield for Eni. He raised his price target for the shares to EUR 16.50 from EUR 15.50. Herrmann moved to a Hold rating on Total following the recent "strong relative performance" of the shares. His price target for the stock of EUR 52 remains unchanged. The analyst calls BP (BP) and Royal Dutch Shell (RDS.A) his most preferred names in European Integrated Oil.
DGICA Donegal Group
$15.07

-0.11 (-0.72%)

10/31/17
BOSC
10/31/17
UPGRADE
BOSC
Outperform
Donegal Group upgraded to Outperform from Neutral at Boenning & Scattergood
Boenning & Scattergood analyst Robert Farnan upgraded Donegal Group to Outperform with a $19 price target following the Q3 beat. The analyst said the company has good growth prospects and management is implementing strategies to improve future operating performance.
11/01/17
KBWI
11/01/17
UPGRADE
Target $20
KBWI
Outperform
Donegal Group upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Christopher Campbell upgraded Donegal Group to Outperform and raised his price target for the shares to $20 from $18 following the company's Q3 results.
11/01/17
11/01/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Airlines (AAL) upgraded to Overweight from Neutral at JPMorgan with analyst Jamie Baker citing attractive risk/reward following the recent pullback in the shares. 2. Mosaic (MOS) was upgraded to Buy from Neutral at Cleveland Research and to Sector Perform from Underperform at Scotiabank. 3. Cempra (CEMP) upgraded to Neutral from Underperform at Baird with analyst Brian Skorney citing the stock's recent weakness and announcement of its proposed Melinta merger. 4. Weatherford (WFT) upgraded to Buy from Neutral at Seaport Global with analyst Mike Urban telling investors international markets are poised to surprise to the upside and act as catalyst for shares. 5. Donegal Group (DGICA) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Christopher Campbell citing the company's third quarter results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/25/17
BOSC
05/25/17
INITIATION
BOSC
Neutral
Donegal Group initiated with a Neutral at Boenning & Scattergood
Boenning & Scattergood analyst Robert Farnam initiated Donegal Group with a Neutral saying shares have an attractive relative valuation but the market cap is under $430 million, the shares have less publicly-available float than peers and limited liquidity.
AMTD TD Ameritrade
$61.21

-0.04 (-0.07%)

04/09/18
BOFA
04/09/18
UPGRADE
Target $66
BOFA
Buy
TD Ameritrade upgraded to Buy on growth, valuation at BofA/Merrill
As previously reported, BofA/Merrill upgraded TD Ameritrade to Buy from Neutral and raised its price target to $66 from $62. Analyst Michael Carrier views TD Ameritrade's near-term outlook as attractive given healthy new net asset growth, higher interest rates, and strong DARTs. Further, the analyst expects the Scottrade acquisition and capital management flexibility to yield further synergy benefits and upside to margins. Carrier views valuation as "attractive" and thinks additional M&A in the sector is likely, which could create more upside for shares.
04/10/18
04/10/18
INITIATION

Outperform
TD Ameritrade initiated with an Outperform at Bernstein
As previously reported, Bernstein analyst Christian Bolu initiated coverage of TD Ameritrade with an Outperform rating and $70 price target saying he expects EPS run-rate to more than double to $4.50-$5 through 2020 as macro tailwinds are supported by realization of Scottrade expense/revenue synergies and execution of CEO Tim Hockey's innovative growth initiatives.
04/09/18
BERN
04/09/18
INITIATION
BERN
Outperform
TD Ameritrade initiated with an Outperform at Bernstein
04/09/18
04/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Motors (GM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying he sees room for positive earnings revisions for GM, Ford (F) and Fiat Chrysler (FCAU) as investors better understand the impact on U.S. pick-up truck sales from a potential passage of a U.S. infrastructure bill. 2. TD Ameritrade (AMTD) upgraded to Buy from Neutral at BofA/Merrill with analyst Michael Carrier saying he views TD Ameritrade's near-term outlook as attractive given healthy new net asset growth, higher interest rates, and strong DARTs. 3. Comerica (CMA) upgraded to Outperform from Neutral at Wedbush with analyst Peter Winter saying he sees several levers that should drive above average earnings per share growth over the next two years, including margin expansion, potential resumption of loan growth, and above average capital returns. 4. Agilent (A) upgraded to Buy from Neutral at Goldman Sachs with analyst Patrick Donnelly saying he sees an attractive fundamental backdrop across Tools. 5. Discover (DFS) and Ally Financial (ALLY) were upgraded to Equal Weight from Underweight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
WHR Whirlpool
$150.31

0.885 (0.59%)

01/29/18
RBCM
01/29/18
NO CHANGE
Target $200
RBCM
Sector Perform
Whirlpool price target raised to $200 from $184 at RBC Capital
RBC Capital analyst Michael Eisen raised his price target on Whirlpool to $200 and kept his Sector Perform rating after inline Q4 earnings and below-consensus FY18 outlook. Eisen says the unexpected mix benefit in Q4 adds to the confidence of higher like-for-like pricing this year, but also notes soft shipments across the regions and signs of decelerating industry growth. The analyst contends there is still some potential upside to guidance, since it does not include FX tailwinds, the positive impact of U.S. tax reform on consumer demand, and the recently approved tariffs on large residential washer imports.
01/26/18
01/26/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Starbucks (SBUX) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Karen Holthouse removed Starbucks (SBUX) from the Conviction Buy List citing another reduction in estimates and risks to back-half weighted guidance. 2. Bed Bath & Beyond (BBBY) downgraded to Underweight from Neutral at JPMorgan with analyst Christopher Horvers saying the stock has run up 16% since the House passed the tax bill in November, and recent estimate revisions suggest the Street is assuming 50% flow through of tax savings. 3. Whirlpool (WHR) downgraded to Sector Weight from Overweight at KeyBanc with analyst Kenneth Zener citing expectations the stock's past trading range will hold. 4. Newell Brands (NWL) downgraded to Sector Perform from Outperform at RBC Capital with analyst Nik Modi saying the forward estimates no longer appear trustworthy after the company's third downward revision in guidance in less than six months. 5. Fortinet (FTNT) downgraded to Market Perform on valuation at Raymond James with analyst Michael Turits citing strong relative shares performance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/04/18
GSCO
04/04/18
DOWNGRADE
Target $135
GSCO
Sell
Whirlpool downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Samuel Eisner downgraded Whirlpool to Sell and cut his price target for the shares to $135 from $164. The analyst sees a price/cost imbalance with medium term competition risk. Eisner believes Whirlpool "operates in one of the weakest industries for pricing power" and sees risk to the company's guidance. Whirlpool's cyclical positioning could further exacerbate the competitive environment while raw material inflation puts estimates at risk, Eisner tells investors in a research note.
04/09/18
BOFA
04/09/18
NO CHANGE
Target $165
BOFA
Neutral
Whirlpool price target lowered to $165 from $190 at BofA/Merrill
BofA/Merrill analyst Curtis Nagle lowered his price target for Whirlpool to $165 from $190 saying that lower growth and late cycle positioning justifies a lower multiple. The analyst reiterates a Neutral rating on the shares.
TVTY Tivity Health
$39.50

-0.6 (-1.50%)

02/23/18
CANT
02/23/18
NO CHANGE
Target $53
CANT
Overweight
Tivity Health price target raised to $53 from $45 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for Tivity Health to $53 saying the company last night reported a "strong" Q4 and "solid" 2018 outlook. The company continues to benefit from strong growth across its three platforms: SilverSneakers, Prime Fitness and WholeHealth Living, Halper tells investors in a post-earnings research note. He reiterates an Overweight rating on the name.
02/23/18
BRRR
02/23/18
NO CHANGE
Target $47
BRRR
Outperform
Tivity Health price target raised to $47 from $40 at Barrington
Barrington analyst Michael Petusky raised his price target for Tivity Health to $47 saying the "big" upside in Q4 and "strong" 2018 guidance add to his conviction. The analyst believes "material upside remains" in the shares and keeps an Outperform rating on the name.
11/06/17
OPCO
11/06/17
NO CHANGE
OPCO
Tivity Health oversold on UnitedHealth news, says Oppenheimer
Oppenheimer analyst Mohan Naidu views Tivity Health (TVTY) as oversold after UnitedHealth (UNH) said its Optum Fitness Advantage program will be available, at no additional cost, to Individual Medicare Advantage plans members in 11 states, starting January 2018. The analyst believes this is only for the individual market and that Tivity's SilverSneakers will be available for all group members. Further, he notes that Tivity management confirmed that their initial 2018 guidance already contemplates the impact of the UnitedHealth rollout. While it is possible that the Optum Fitness introduction is a precursor to a broader program, SilverSneaker's name and trust drives a lot of enrollment decisions and will likely be a deciding factor in the expansion of this new offering, Naidu tells investors in an intraday research note. Tivity Health is down 31%, or $14.70, to $33.35 in afternoon trading.
11/07/17
BRRR
11/07/17
NO CHANGE
Target $40
BRRR
Outperform
Tivity Health price target lowered to $40 from $46 at Barrington
Barrington analyst Michael Petusky lowered his price target for Tivity Health (TVTY) to $40 after UnitedHealth (UNH), which represents about 15%-17% of Tivity's overall revenue, disclosed that it would be competing with the company's SilverSneakers program in 11 states as of January 1, 2018. Based on the analyst's conversation last night with management, he still suspects UnitedHealth will continue to be a material customer of Tivity through at least the end of the contract in 2020. Petusky cations, however, that he has no real clarity on how much additional business could transition to United's internal offering beyond 2018. He maintains an Outperform rating on Tivity Health.
BRO Brown & Brown
$26.56

0.6 (2.31%)

11/08/17
SBSH
11/08/17
DOWNGRADE
Target $47
SBSH
Sell
Brown & Brown downgraded to Sell from Neutral at Citi
Citi analyst James Naklicki downgraded Brown & Brown to Sell saying the shares are now overvalued following a 36% run since the election. The analyst cut his price target for the stock to $47 from $49. He sees Brown & Brown's earnings growth being just 5%-6% over the next three years, or much lower than its peers.
12/06/17
12/06/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AIG (AIG) upgraded to Hold from Sell at Deutsche Bank with analyst Joshua Shanker sayign the stock "might have found a bottom" after dropping 8% since the third quarter results on November 2. Brown & Brown (BRO) upgraded to Buy from Hold at SunTrust with analyst Mark Hughes saying the company stands to benefit from commission gains in the Florida market, contribution from the company's sales incentive program, reduced investments costs, and the anticipated tax reform impact which could add up to 55c to the fiscal 2019 earnings per share target of $2.25. 3. L3 Technologies (LLL) upgraded to Outperform from Sector Perform at RBC Capital with analyst Matt McConnell citing the company's investor day presentation. McConnell says the event highlighted the company's position combining the "best-in-defense runway for operating margin improvement, near-term organic growth acceleration, and bolt-on M&A potential". 4. Carnival (CCL) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Jamie Rollo stating that the firm's survey of U.S. travel agents suggested strong demand for cruises in November, which he notes is usually a slow month for bookings. 5. Express Scripts (ESRX) upgraded to Market Perform from Underperform at Bernstein with the firm citing improved upside risks from potential policy and competitor actions and valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/06/17
RHCO
12/06/17
UPGRADE
Target $63
RHCO
Buy
Brown & Brown upgraded to Buy at SunTrust on gains in Florida market
As noted earlier, SunTrust analyst Mark Hughes upgraded Brown & Brown to Buy from Hold and raised his price target to $63 from $52. Hughes notes the company stands to benefit from commission gains in the Florida market, contribution from the company's sales incentive program, reduced investments costs, and the anticipated tax reform impact which could add up to 55c to the FY19 EPS target of $2.25. The analyst is especially positive on the Florida market impact, where post-Irma moratorium rolls off after 90 days, leading to property insurance rates going up 5%-20%.
12/06/17
RHCO
12/06/17
UPGRADE
RHCO
Buy
Brown & Brown upgraded to Buy from Hold at SunTrust
ABX Barrick Gold
$12.93

-0.23 (-1.75%)

03/02/18
ARGS
03/02/18
DOWNGRADE
ARGS
Hold
Barrick Gold downgraded to Hold from Buy at Argus
As reported earlier, Argus analyst David Coleman downgraded Barrick Gold to Hold from Buy, stating that despite the sharp decline in the stock price this year, earnings are likely to remain flat or decline further in the coming quarters. Coleman points to the company's recent lower production forecast along with the likelihood of higher near term extraction costs, along with its ongoing tax dispute with the government of Tanzania where it operates the Acacia mines. In the long run, Coleman still expects Barrick Gold earnings to recover on "stable to modestly higher gold prices" and continued debt reduction efforts.
04/23/18
ADAM
04/23/18
DOWNGRADE
ADAM
Hold
Barrick Gold downgraded to Hold from Buy at Canaccord
03/12/18
RBCM
03/12/18
UPGRADE
RBCM
Outperform
Barrick Gold upgraded to Outperform from Sector Perform at RBC Capital
03/12/18
RBCM
03/12/18
UPGRADE
Target $16
RBCM
Outperform
Barrick Gold upgraded to Outperform at RBC Capital on 'relative value'
As reported earlier, RBC Capital analyst Stephen Walker upgraded Barrick Gold to Outperform from Sector Perform, saying the impact of the company's higher cost guidance has been priced in while the current valuation offers an attractive entry point. The analyst also sees the resolution of the Acacia mine dispute and production updates as potential near term catalysts. Walker trims his price target on Barrick Gold to $16 from $17.
OI Owens-Illinois
$21.76

0.13 (0.60%)

02/07/18
VERT
02/07/18
UPGRADE
Target $27
VERT
Buy
Owens-Illinois upgraded to Buy from Hold at Vertical Research
Vertical Research analyst Chip Dillon upgraded Owens-Illinois to Buy and raised his price target for the shares to $27 from $26. The analyst believes the company is benefiting from volume growth in the Mexican beer market.
04/26/17
SBSH
04/26/17
NO CHANGE
Target $26
SBSH
Buy
Owens-Illinois turnaround remains on track, says Citi
Citi analyst Anthony Pettinari raised his price target for Owens-Illinois to $26 from $24 following the company's Q1 results. Owens' operational turnaround remains on track, Pettinari tells investors in a post-earnings research note. He views the shares as undervalued and keeps a Buy rating on the name.
09/05/17
UBSW
09/05/17
INITIATION
Target $26
UBSW
Neutral
Owens-Illinois initiated with a Neutral at UBS
UBS analyst Edlain Rodriguez started Owens-Illinois with a Neutral rating and $26 price target. The analyst views the risk/reward as fairly balanced at current valuation levels.
09/05/17
09/05/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Owens-Illinois (OI) initiated with a Neutral at UBS. 2. Akamai (AKAM) initiated with a Neutral at Credit Suisse. 3. Zealand Pharma (ZEAL) was initiated with a Buy at Needham and Guggenheim while being initiated with an Overweight at Morgan Stanley. 4. YogaWorks (YOGA) was initiated with an Outperform at Cowen, an Overweight at Stephens, and a Buy at Roth Capital and Guggenheim. 5. Red Hat (RHT) initiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
EPZM Epizyme
$15.25

-0.65 (-4.09%)

03/14/18
RHCO
03/14/18
NO CHANGE
Target $27
RHCO
Buy
Epizyme price target raised to $27 from $21 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Epizyme to $27, saying the company's Q4 earnings call reiterated expectations of on-track data flow in epithelioid sarcoma registrations / NDA filing later this year, the combo data for DLBCL, and the follicular lymphoma data and registration path in the second half of 2018. Lawson keeps his Buy rating and attributes his price target revision to the treatment's higher probability of success.
04/11/18
JEFF
04/11/18
NO CHANGE
Target $27
JEFF
Buy
Epizyme recent pullback creates attractive risk/reward, says Jefferies
Jefferies analyst Michael Yee believes the recent pullback in shares of Epizyme creates an attractive risk/reward ahead of a "catalyst-rich" 2018. The company's market capitalization could appreciate from less than $1B to $2-$3B over time if data in the second half "starts to play out like we expect," Yee tells investors in a research note. He thinks Epizyme's mixed shelf filing last week has some investors concerned that an equity financing could be possible in the near term. Yee believes, however, that the filing "simply replaces and refreshes" an existing one that has always been on hand as opposed to suggesting the company is getting ready to raise near-term cash. The analyst keeps a Buy rating on the shares with a $27 price target.
02/01/18
02/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Epizyme (EPZM) initiated with a Buy at Roth Capital. 2. Take-Two (TTWO) initiated with an Overweight at Morgan Stanley. 3. AMERI Holdings (AMRH) initiated with an Outperform at Northland. 4. Simply Good Foods (SMPl) initiated with a Buy at SunTrust. 5. Zynerba (ZYNE) assumed with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/01/18
ROTH
02/01/18
INITIATION
Target $24
ROTH
Buy
Epizyme initiated with a Buy at Roth Capital
Roth Capital analyst Jotin Marango started Epizyme with a Buy rating and $24 price target as he believes its lead agent tazemetostat, an inhibitor of the histone methyltrasferase EZH2, has laid out a sufficiently wide clinical footprint, and is sufficiently close to an NDA in several indications, that even his conservative approach of ranking its clinical programs shows that the company still remains undervalued.
AGO Assured Guaranty
$35.90

-0.81 (-2.21%)

06/07/17
BTIG
06/07/17
NO CHANGE
BTIG
MBIA may be more likely to accept takeover offer, says BTIG
BTIG analyst Mark Palmer believes that S&P's decision to place the credit rating of MBIA's (MBI) National Public Finance Guarantee Corp.on credit watch negative could increase the chances of MBIA selling itself to Assured Guaranty (AGO). Plamer thinks that such a deal would be a "win-win" for MBIA and Assured Guaranty. He keeps Buy ratings on both stocks.
10/05/17
MKMP
10/05/17
NO CHANGE
MKMP
Bond insurer decline could be opportunity, says MKM Partners
After President Trump said all of Puerto Rico's debt would have to be wiped out, MKM PArtners analyst Harry Fong does not expect the debt to actually be wiped out. He believes that taking this step would violate the principles of contract law and could destroy the municipal bond market. The analyst adds that the bond insurers will not face liquidity issues if Puerto Rico's debt is wiped out. He believes that the decline in their stocks could prove to be a buying opportunity. He keeps Buy ratings on Assured Guaranty (AGO) and MBIA (MBI), and he maintains a Neutral rating on Ambac (AMBC).
12/20/17
KBWI
12/20/17
INITIATION
Target $47
KBWI
Outperform
Keefe Bruyette starts Assured Guaranty with Outperform, $47 target
Keefe Bruyette analyst Bose George started Assured Guaranty with an Outperform rating and $47 price target. While the company's losses from the Puerto Rican debt crisis could be material, a more likely scenario is a resolution that results in losses that are already incorporated in the valuation of the shares, George tells investors in a research note. Further, the analyst believes higher interest rates should improve the landscape for new business.
02/16/18
BTIG
02/16/18
NO CHANGE
BTIG
BTIG says PREPA request rejection a 'huge' positive for Assured Guaranty, MBIA
BTIG analyst Mark Palmer said that U.S. District Court Judge Laura Taylor Swain's rejection of the financial oversight board's effort to prime the bondholders of the Puerto Rico Electric Power Authority, or PREPA, is a "huge" positive for municipal bond insurers Assured Guaranty (AGO) and MBIA (MBI). Each have significant insured exposure to PREPA's debt and the rejection of PREPA's effort to gain approval for a $1B DIP loan issued by the Puerto Rico government that would have primed the utility's bondholders was a big win, said Palmer. He also believes the ruling had broader implications for them and fellow municipal bond insurer Ambac Financial (AMBC), which has no insured exposure to PREPA but still filed a motion opposing the DIP loan. MBIA shares are up 6.8% in early trading while Assured Guaranty is up about 3.8%.
CASA Casa Systems
$29.81

-0.35 (-1.16%)

01/09/18
01/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ormat Technologies (ORA) initiated with a Buy at Guggenheim. 2. Chaparral Energy (CHPE) initiated with an Outperform at Imperial Capital. 3. Genesee & Wyoming (GWR) initiated with an Overweight at JPMorgan. 4. Newmark (NMRK) was initiated with a Buy at Sandler O'Neill, BofA/Merrill, and Goldman Sachs, as well as an Outperform at Wedbush. 5. Casa Systems (CASA) was initiated with an Outperform at Northland, William Blair, and Raymond James, a Buy at Stifel, as well as an Equal Weight at Morgan Stanley and Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/18
MACQ
01/10/18
INITIATION
Target $24
MACQ
Outperform
Casa Systems initiated with an Outperform at Macquarie
Macquarie analyst Sarah Hindlian initiated Casa Systems with an Outperform and $24 price target. The analyst expects Casa to continue to gain share it its core $2B CY17 Converged Cable Access Platform market, benefiting from software defined solutions, expansion beyond its strong core position to adjacent areas of network transformation solutions.
01/09/18
NORL
01/09/18
INITIATION
Target $25
NORL
Outperform
Casa Systems initiated with an Outperform at Northland
Northland analyst Tim Savageaux initiated Casa Systems with a Buy and $25 price target. The analyst believes Casa is an emerging IP broadband access platform leader, leveraging a strong position in a market for IP Cable networks, that he anticipates to inflect upward in 2018, into wireless and Telco IP access markets.
03/07/18
STFL
03/07/18
NO CHANGE
Target $27
STFL
Buy
Casa Systems price target raised to $27 after first public report at Stifel
Stifel analyst Patrick Newton said Casa Systems' revenue topped his expectations in the company's first report since coming public and its pro forma EPS of $1.07 was "well above" his 34c forecast, driven by higher than expected gross margin, a lower tax rate and lower than expected shares outstanding. DOCSIS 3.1 trends are accelerating, management continues to see a ramp of DAA in the second half and wireless momentum is building, said Newton, who raised his price target on Casa shares to $27 from $23 and keeps a Buy rating on the stock.
BBBY Bed Bath & Beyond
$17.35

0.22 (1.28%)

04/23/18
WELS
04/23/18
INITIATION
Target $16
WELS
Underperform
Bed Bath & Beyond initiated with an Underperform at Wells Fargo
Wells Fargo analyst Zachary Fadem initiated Bed Bath & Beyond with an Underperform and $16 price target.
04/12/18
04/12/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Paycom (PAYC) downgraded to Equal Weight from Overweight at Barclays with analyst Raimo Lenschow saying the stock has meaningfully outperformed over the last year while estimate revisions have been limited. 2. J.B. Hunt (JBHT) downgraded to Sector Weight from Overweight at KeyBanc. 3. Devon Energy (DVN) downgraded to Outperform from Focus List at Scotia Howard Weil. 4. PJT Partners (PJT) downgraded to Hold from Buy at Sandler O'Neill with analyst Sumeet Mody saying after appreciating 17% year-to-date, the stock is approaching fair value. 5. Bed Bath & Beyond (BBBY) downgraded to Underperform at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/12/18
LOOP
04/12/18
NO CHANGE
LOOP
Bed Bath & Beyond price target lowered to $18 from $23 at Loop
Loop Capital analyst Anthony Chukumba lowered his price target on Bed Bath & Beyond to $18 from $23 and maintained a Hold rating following the company's "much worse-than-expected" FY18 earnings guidance and subsequent sell-off.
04/12/18
04/12/18
DOWNGRADE

Underperform
Bed Bath & Beyond downgraded to Underperform at Raymond James
As previously reported, Raymond James analyst Beryl Bugatch downgraded Bed Bath & Beyond to Underperform from Market Perform following quarterly results. Despite the array of initiatives announced by management, a key issue for the analyst is that the fleet of over 1,000 legacy Bed Bath & Beyond stores continue to deliver in-store mid-single-digit comp sales declines. Without some underlying growth in management generated earnings over the next two years, shareholder value is likely to erode further, he adds. Nonetheless, Bugatch points out that at its current valuation, Bed Bath may attract "activist" interest.

TODAY'S FREE FLY STORIES

02:55
09/20/18
09/20
02:55
09/20/18
02:55
General news
FX Update: Narrow ranges have been prevailing »

FX Update: Narrow ranges…

02:10
09/20/18
09/20
02:10
09/20/18
02:10
General news
FX Action: USD-JPY has drifter lower »

FX Action: USD-JPY has…

01:50
09/20/18
09/20
01:50
09/20/18
01:50
General news
Asian Market Wrap: »

Asian Market Wrap:…

23:50
09/19/18
09/19
23:50
09/19/18
23:50
General news
Nellie Liang »

Nellie Liang will be…

CRM

Salesforce

$152.88

-3.12 (-2.00%)

, CPCAY

Cathay Pacific

$0.00

(0.00%)

21:04
09/19/18
09/19
21:04
09/19/18
21:04
Hot Stocks
Cathay Pacific to partner with Salesforce on digital transformation »

Salesforce (CRM)…

CRM

Salesforce

$152.88

-3.12 (-2.00%)

CPCAY

Cathay Pacific

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 03

    Mar

UCTT

Ultra Clean

$13.42

-0.13 (-0.96%)

21:02
09/19/18
09/19
21:02
09/19/18
21:02
Hot Stocks
Ultra Clean announces fire at a plant in Korea »

Ultra Clean Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$291.22

0.26 (0.09%)

, SPX

S&P 500

$0.00

(0.00%)

21:00
09/19/18
09/19
21:00
09/19/18
21:00
General news
President Trump to nominate Nellie Liang to Federal Reserve Board of Governors »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$291.22

0.26 (0.09%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EB

Eventbrite

$0.00

(0.00%)

20:53
09/19/18
09/19
20:53
09/19/18
20:53
Syndicate
Eventbrite 10M share IPO priced at $23.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

EFX

Equifax

$134.27

-3.78 (-2.74%)

20:40
09/19/18
09/19
20:40
09/19/18
20:40
Hot Stocks
Equifax UK arm fined GBP500K for security breach in 2017 »

The Information…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 20

    Sep

  • 06

    Nov

BSVN

Bank7

$0.00

(0.00%)

20:29
09/19/18
09/19
20:29
09/19/18
20:29
Syndicate
Bank7 3.4M share IPO priced at $19.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

THO

Thor Industries

$105.72

2.44 (2.36%)

, DRI

Darden

$117.90

-1.03 (-0.87%)

20:25
09/19/18
09/19
20:25
09/19/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

THO

Thor Industries

$105.72

2.44 (2.36%)

DRI

Darden

$117.90

-1.03 (-0.87%)

SANW

S&W Seed

$3.15

0.1 (3.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 20

    Sep

  • 11

    Oct

LGCY

Legacy Reserves

$4.78

-0.18 (-3.63%)

19:34
09/19/18
09/19
19:34
09/19/18
19:34
Initiation
Legacy Reserves initiated at Seaport Global »

Legacy Reserves initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMT

Core Molding

$7.75

-0.15 (-1.90%)

19:07
09/19/18
09/19
19:07
09/19/18
19:07
Hot Stocks
Core Molding names Eric Palomaki VP of Operations »

Core Molding Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMNI

Rimini Street

$6.92

0.33 (5.01%)

19:07
09/19/18
09/19
19:07
09/19/18
19:07
Hot Stocks
Rimini Street obtains Australian single touch payroll certification »

Rimini Street announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$37.30

0.2 (0.54%)

, LCI

Lannett

$4.85

0.15 (3.19%)

18:56
09/19/18
09/19
18:56
09/19/18
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Herman…

MLHR

Herman Miller

$37.30

0.2 (0.54%)

LCI

Lannett

$4.85

0.15 (3.19%)

AVP

Avon Products

$2.32

0.03 (1.31%)

NGD

New Gold

$1.10

0.03 (2.80%)

AMD

AMD

$31.20

-0.73 (-2.29%)

RHT

Red Hat

$143.38

0.59 (0.41%)

MTEM

Molecular Templates

$6.25

2.15 (52.44%)

CRSP

Crispr Therapeutics

$51.90

-1.27 (-2.39%)

KOS

Kosmos

$9.35

0.04 (0.43%)

VKTX

Viking Therapeutics

$19.64

0.17 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 21

    Sep

  • 23

    Sep

  • 27

    Sep

  • 01

    Oct

  • 20

    Sep

  • 21

    Sep

  • 21

    Sep

  • 21

    Sep

LCI

Lannett

$4.85

0.15 (3.19%)

18:49
09/19/18
09/19
18:49
09/19/18
18:49
Hot Stocks
Breaking Hot Stocks news story on Lannett »

MintBroke International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$84.43

-0.86 (-1.01%)

18:43
09/19/18
09/19
18:43
09/19/18
18:43
Periodicals
Nike has sold out 61% more merchandise after Kaepernick ad, Reuters says »

Nike has sold out 61%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 20

    Sep

  • 25

    Sep

ADVM

Adverum Biotechnologies

$5.85

0.05 (0.86%)

18:38
09/19/18
09/19
18:38
09/19/18
18:38
Hot Stocks
Adverum Biotechnologies receives fast track designation for ADVM022 gene therapy »

Adverum Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

BTI

British American Tobacco

$46.87

-0.475 (-1.00%)

18:11
09/19/18
09/19
18:11
09/19/18
18:11
Hot Stocks
British American Tobacco CEO Durante to retire April 1, 2019 »

British American Tobacco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRNY

Kearny Financial

$13.75

0.25 (1.85%)

18:02
09/19/18
09/19
18:02
09/19/18
18:02
Hot Stocks
Kearny Financial declares special cash dividend of 16c per share »

Kearny Financial has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVA

Avista

$51.50

0.01 (0.02%)

18:00
09/19/18
09/19
18:00
09/19/18
18:00
Hot Stocks
Avista, Hydro One extend merger end date »

Hydro One Limited and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,926.27

-14.93 (-0.77%)

17:57
09/19/18
09/19
17:57
09/19/18
17:57
Periodicals
Amazon leaks new Alexa smart plug and a subwoofer, Verge says »

According to the Verge,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$163.06

2.75 (1.72%)

17:45
09/19/18
09/19
17:45
09/19/18
17:45
Periodicals
Facebook sets up 'War Room' for safeguarding elections, NY Times says »

After Facebook gained…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

RRTS

Roadrunner

$1.16

-0.065 (-5.33%)

17:45
09/19/18
09/19
17:45
09/19/18
17:45
Syndicate
Roadrunner files S-1 for rights offering to existing holders »

Roadrunner announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$26.45

0.3 (1.15%)

17:35
09/19/18
09/19
17:35
09/19/18
17:35
Hot Stocks
Associated Banc-Corp announces $200M share repurchase program »

Associated's Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.